Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions
Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions
复制标题
美国生物仿制药依泊汀：南方网络对不良反应的看法
DOI：
10.1007/978-3-031-04402-1_2
复制
发表时间：
2022
影响因子：
--
通讯作者：
Bennett Charles L.
中科院分区：
文献类型：
--
作者：
Nagai Sumimasa;Witherspoon Bartlett;Nabhan Chadi;Bennett Charles L.
生物相似药物是专利生物制品的近复制品，旨在提供获得更便宜、高度相似的参考(先前批准的)生物制剂版本的途径(Kozlowski等人。收录于《医学杂志》365：385-388,2011)。生物促红细胞生成素在全球每年的药物支出中占18亿美元(主要用于治疗慢性肾脏疾病引起的贫血或癌症化疗引起的贫血)。
Biosimilar drugs, close copies of patented biologicals, are intended to provide access to less expensive, highly similar versions of reference (previously approved) biological agents (Kozlowski et al. in N Engl J Med 365:385–388, 2011). The biological epoetin accounts for $1.8 billion in drug spending annually worldwide (primarily for the treatment of anemia due to chronic kidney disease or anemia due to cancer chemotherapy.)